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ranscatheter Aortic Valve Implantation
eview of the Nature, Management, and Avoidance of Procedural Complications
ean-Bernard Masson, MD,* Jan Kovac, MD,† Gerhard Schuler, MD,‡ Jian Ye, MD,*
nson Cheung, MD,* Samir Kapadia, MD,§ Murat E. Tuzcu, MD,§ Susheel Kodali, MD,
artin B. Leon, MD, John G. Webb, MD*
ancouver, Canada; Leicester, United Kingdom; Leipzig, Germany; Cleveland, Ohio;
nd New York, New York
ranscatheter aortic valve implantation (TAVI) is becoming a reality in the management of patients
ith severe aortic stenosis and high or prohibitive risk for standard surgical management. Current un-
erstanding of the potential adverse events associated with this procedure is limited. Risks associated
ith TAVI differ from those related to surgical valve replacement and include vascular injury; stroke;
ardiac injury such as heart block, coronary obstruction, and cardiac perforation; paravalvular leak; and
alve misplacement. The clinical experience of multiple centers experience with different valve implan-
ation systems and techniques was reviewed. Awareness of how complications occur might help in
heir avoidance, recognition, and management. Ultimately, improved understanding of the potential
omplications associated with TAVI might help improve outcomes and allow wider application of this
herapy. (J Am Coll Cardiol Intv 2009;2:811–20) © 2009 by the American College of Cardiology
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2ranscatheter aortic valve implantation (TAVI)
s increasingly recognized as a viable therapeutic
ption for patients with severe, symptomatic
ortic stenosis and high risk for conventional
urgery. Registries from multiple centers have
hown TAVI can be accomplished in selected
igh-risk patients with outcomes that compare
avorably with the outcome of standard valve
eplacement as predicted by validated operative
isk assessment tools (1– 6).
Despite being less invasive than open-chest
ortic valve replacement, TAVI remains asso-
iated with the potential for serious complica-
ions. We review the potential complications of
rom the *Divisions of Cardiology and Cardiac Surgery, St. Paul’s
ospital, University of British Columbia, Vancouver, Canada; †Depart-
ent of Cardiology, University Hospitals, Leicester, United Kingdom;
Department of Cardiology, Heart Center, Leipzig, Germany; §Depart-
ent of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio;
nd the Center for Interventional Vascular Therapy, Columbia Univer-
ity Medical Center, New York, New York.i
anuscript received March 10, 2009; revised manuscript received July 2,
009, accepted July 27, 2009.AVI and discuss their prevention, diagnosis,
nd management.
verview of procedure. Two TAVI systems have
een wide clinical application: the balloon-expandable
dwards valve (Edwards Lifesciences, Irvine, Califor-
ia), and the self-expandable CoreValve ReValving
ystem (CoreValve, Irvine, California). Both systems
ave been extensively described elsewhere (6–8).
etrograde transarterial or antegrade transapical ap-
roaches are currently used to access the aortic valve.
alloon aortic valvuloplasty is performed before valve
nsertion to facilitate passage of the prosthesis
hrough the stenotic native valve. With the balloon-
xpandable valve, ventricular burst pacing is used to
ecrease transvalvular flow and avoid expulsion of the
ystem toward the aorta upon deployment.
ccess and Delivery
rterial injury. The relatively large diameter of
he delivery catheter has been a major limitation
f transarterial TAVI. Early systems used 22- to
5-F sheaths (outer diameter 9 to 10 mm), and
n the absence of adequate screening the inci-
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812ence of arterial dissection and perforation was relatively
igh. Newer low-profile systems (e.g., CoreValve and
dwards NovaFlex) are compatible with smaller 18-F
heaths (outer diameter approximately 7 mm). It is
easonable to assume that the risk of vascular complica-
ions is reduced with the use of these lower-profile
elivery systems. With technological advances, delivery
atheter and sheath size will likely decrease further,
hich should be associated with further reductions in the
isk of vascular injury and less stringent criteria for a
ransarterial approach.
Angiography and multislice computed tomography are the
ain imaging modalities used to assess the presence and
everity of ilio-femoral disease and determine the feasibility of
n arterial approach. Minimal lumen diameter as well as the
mount and distribution of atheroma, tortuosity, and calcifi-
ation will determine the risk for vascular injury related to
heath insertion. Ideally the minimal lumen diameter should
xceed the diameter of the delivery system. However, in the
bsence of extensive calcification, bulky atheroma, or severe
ortuosity, short segments of relatively compliant artery 1 to 2
m smaller in diameter than the intended sheath can often be
afely cannulated.
Dissection or perforation of
the ilio-femoral arteries might
occur in the presence of exces-
sively traumatic sheath inser-
tion (Fig. 1A). Dissection of
the ascending or descending
aorta can similarly occur due to
catheter trauma (Fig. 2) or as
Figure 1. Vascular Injury
(A) Dissection of the right iliac artery. (B) Occlusion balloon (Occlusion Cathete
bbreviations
nd Acronyms
V  left
entricle/ventricular
AVI  transcatheter aortic
alve implantationBalloon Catheter, Cook Medical, Inc., Bloomington, Indiana) inﬂated in the left iliac an unpredictable complication of aortic valvuloplasty (1).
onocclusive retrograde arterial dissection will com-
only heal once antegrade flow is restored; therefore
imited dissections are often best managed conservatively.
ore extensive arterial dissection can be managed with
ndovascular stenting although on occasion surgical re-
air might be necessary.
Vascular perforation leading to retroperitoneal hemor-
hage is a more dramatic potential complication of TAVI.
uccessful management requires a high level of suspicion,
hould sudden, unexplained hypotension appear. When
he large arterial sheath is occlusive, perforation might
ecome evident only after sheath removal. Volume ex-
ansion and angiographic assessment should be per-
ormed without delay. Immediate reinsertion of the
cclusive sheath over a guidewire or placement of a highly
ompliant occlusion balloon proximal to the area of
uspected perforation typically provides rapid and rela-
ively reliable control of bleeding (9), allowing time for
efinitive management (Figs. 1B and 1C). Covered stents
r percutaneous endografts might be adequate, although
urgical repair might be necessary. After uncomplicated
ascular closure, ilio-femoral angiography performed
rom the contralateral femoral access site allows rapid
dentification and, if necessary, management of vascular
omplications.
An unusual presentation peculiar to a large, occlusive
emoral sheath is a tendency for the sheath and endothe-
ium to adhere. Sheath withdrawal is met with resistance
nd possible complete arterial avulsion and sudden hem-
rrhage (Fig. 3). The risk of ilio-femoral adherence and
ton Scientiﬁc, Natick, Massachusetts). (C) Occlusion balloon (Coda Occlusionr, Bos
rtery.
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813vulsion can be minimized with smaller sheaths, periodic
heath rotation, and early sheath removal. When this
henomenon is suspected, pre-emptive placement of an
cclusion balloon and preparation for possible surgical
epair is prudent.
For patients with unsuitable femoral access, alternatives
nclude the apical, subclavian (10), open iliac or ascending
orta (11) approaches, or reconstruction of ilio-femoral axis
ith stents or grafts. Although a large experience exists with
he apical procedure, experience with the other approaches
s limited.
pical access issues. Direct access to the left ventricle
LV) is typically obtained through an intercostal mini-
horacotomy. The risk for lung injury, pneumothorax, or
leural bleeding seems low. Perhaps the most common
oncern related to the mini-thoracotomy is chest wall
iscomfort and associated potential for respiratory com-
romise and prolonged ventilation (12).
Access to the LV cavity is obtained by needle puncture
Figure 2. Dissection of the Ascending Aorta
(A) Cross-sectional transesophageal echocardiographic and (B) angio-
graphic images (yellow arrows delineate the spiral dissection).ateral to the apex. The ventriculotomy is dilated toccommodate a large sheath and on completion of the
rocedure is repaired with pre-inserted pledgeted sutures.
hort bursts of rapid ventricular pacing to decrease LV
ystolic pressure can be helpful during repair. Post-
rocedural low-grade bleeding from the access site might
esult in cardiac tamponade and require further repair,
hereas management of large tears might require insti-
ution of cardiopulmonary support. In rare cases, pseu-
oaneurysm formation at the site of ventricular repair has
een observed weeks to months after TAVI (Fig. 4).
lthough pseudoaneurysms might be initially asymptom-
tic, they are typically progressive and might require
ntervention.
troke. The most frequent etiology of procedural stroke
s likely to be atheroembolism from the ascending aorta
r the aortic arch. Other potential causes include calcific
mbolism from the aortic valve, thromboembolism from
atheters, air embolism from LV cannulation, prolonged
ypotension, and dissection of arch vessels (13). Balloon
ilation of the native valve is typically performed before
alve implantation to ease insertion of the crimped
rosthesis. Repeated or overly aggressive valvuloplasty
ight be associated with an increased risk of emboliza-
ion of calcific material from the aortic valve (14) and
hould be avoided.
The incidence of stroke varies in the published reports
s the consequence of the learning curve, the evolution in
echnique, and equipment but also the completeness of
eurologic assessment. With current devices and experi-
nce, stroke rate ranges from 0% to 10% (2,3,5,15,16).
ome authors have suggested that stroke risk might be
ower with transapical access due to less manipulation in
he aortic arch (1,2), but this has not been a universal
nding (5,15). In the future, increased procedural expe-
ience, less traumatic valve delivery systems, screening for
Figure 3. Arterial Avulsion
The vascular endothelium adhered to the sheath during the procedure
with complete avulsion of the iliac artery upon sheath removal.
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814hick aortic atheroma, and possibly embolic protection
evices currently under development might lower the risk
f stroke. Procedural anticoagulation to reach a target
ctivated clotting time over 250 s is generally suggested.
The longer-term thromboembolic risk associated with
ranscatheter valves is currently unknown. Empiric dual
ral antiplatelet therapy is generally recommended for 3
o 6 months, followed by long-term daily low-dose
spirin.
ositioning and Deployment
mproper positioning. An ideal transcatheter aortic prosthesis
ould restrain the native leaflets and relieve stenosis without
nnecessary contact with the surrounding structures. A valve
xtending excessively into the ventricle or the aorta might be
ssociated with adverse events such as mitral insufficiency,
rrhythmias or aortic injury.
Prosthesis embolization immediately after deployment
s generally the result of a gross error in positioning or
jection of the device by an effective ventricular contrac-
ion during deployment (Fig. 5). Embolization to the
orta is well-tolerated so long as coaxial wire position is
aintained, preventing the valve from flipping over to
bstruct antegrade flow. Typically the valve can be snared
r repositioned with a partially inflated valvuloplasty
alloon into a stable position in the aorta. A TAVI
eattempt is often successful, although an alternative
pproach might be advisable when the reason for initial
ailure cannot be addressed (17). Embolization to the LV
s far less likely, but in such cases surgical removal might
e the only option (18). The ability to recapture and
osition. (B) The prosthesis is secured in the aorta with no detectable gradi-Figure 4. Apical Pseudoaneurysm
(A) Pseudoaneurysm arising from the left ventricular apex apparent several
weeks after a transapical procedure. The black arrow indicates the valved
stent. (B) Pseudoaneurysm formation after a local wound infection. Ao Figure 5. Embolization
(A) The embolized balloon-expandable valve orientation is maintained by the wire p
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leaﬂet (not the stent itself) seemed to obstruct the ostium.
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815eposition a valve after deployment would clearly be
dvantageous, and such prostheses might become avail-
ble in the upcoming years (19).
oronary obstruction. Coronary obstruction might occur
f an obstructive portion of the valve frame (Fig. 6A) or
he sealing cuff is placed directly over a coronary ostium;
owever, this is exceedingly rare. The presence of open
ells over a coronary ostium is well-tolerated, but al-
hough percutaneous coronary interventions have been
erformed after valve implantation (20), it is likely that
rame struts will prevent or complicate selective coronary
annulation. Of more concern is the possibility of dis-
lacing an unusually bulky, calcified native leaflet over a
oronary ostium (Fig. 7) (7). Although this might be
atal, some cases have been successfully managed by
mmediate percutaneous angioplasty or bypass surgery
2). The risk of coronary occlusion is low but difficult to
ssess and most likely depends on the bulkiness of the
ative leaflets, height of the coronary ostia, and dimen-
ions of the sinus of Valsalva. Echocardiography, aortog-
the ostium. (B) Successful percutaneous intervention restored left coronary
n (arrows) are approximated after valve implantation. (D) At autopsy, theFigure 6. Coronary Obstruction and Frame Deformation
(A) Normal ﬂow in the left coronary artery despite the presence of a stent
strut at the left main coronary ostium. (B) Oval shape of the transcatheter
valve, possibly the result of chest compressions received during a transientFigure 7. Left Main Obstruction
(A) Left main coronary artery occlusion resulting from a bulky leaﬂet displaced over
ﬂow. (C) In a second patient, calciﬁcations from the native aortic leaﬂet and left mai
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816aphy, and multislice computed tomography have been
sed to assess these relationships (21). On occasion
ortography during aortic valvuloplasty might help clarify
otential concerns. At this time no definite criteria exist
o exclude patients on the basis of the risk for coronary
bstruction, but some have suggested that the coronary
stia should be minimally located 14 mm away from the
eaflets insertion.
itral valve injury. Mitral valve injury was first reported in
he setting of the transvenous, transseptal approach to the
ortic valve (22). With this approach the delivery system
rosses the mitral valve with the potential for temporary
itral incompetence (23) or abrasion and laceration of
he anterior mitral leaflet (24). Although this approach is
o longer used, mitral injury might still occur. With the
ntegrade apical approach, a wire can be passed under-
eath a mitral chordae. Advancing a large catheter over
his wire might result in temporary distortion of the
itral valve apparatus or avulsion of a mitral chordae,
eading to acute mitral regurgitation. Resistance to cath-
ter advancement through the ventricle or transient
itral regurgitation assessed by transesophageal echocar-
Figure 8. Delayed Mitral Valve Injury
(A) The stent (double arrow) is in contact with the anterior mitral leaﬂet. Pros
the mitral leaﬂet at the point of contact (single arrow). (B) Ensuing severe mi
secondary to chordeal rupture created (D) severe mitral regurgitation several m
outﬂow tract.iography should alert the operator to this possibility. gewiring or use of a balloon flotation catheter might be
onsidered to avoid subchordal passage.
The ventricular end of a transcatheter prosthesis can be
xpected to contact the anterior mitral curtain. A pros-
hesis extending too far into the LV might interfere with
ovement of the mitral leaflet and cause acute mitral
egurgitation. Surgical removal of such prosthesis might
e necessary, although this seems exceedingly rare. The
ong-term effects of lesser degrees of prosthesis-anterior
itral leaflet contact are unknown, but isolated instances
f late mitral valve injury have been documented (25)
Fig. 8).
aravalvular regurgitation. Minor paravalvular regurgitation
s ubiquitous with current transcatheter valves, but the inci-
ence of moderate or severe paravalvular leaks was greatly
educed by the routine insertion of prostheses larger than the
easured annulus diameter. Initial reports suggested signifi-
ant paravalvular leak in many patients after implantation of
he first-generation balloon-expandable TAVI (22,23), but
ore recent publications report infrequent cases of moderate or
evere paravalvular regurgitation with both systems (3–5).
Mild and even moderate degrees of paravalvular regur-
valve endocarditis 1 year after implantation associated with perforation of
gurgitation. (C) In a second patient, prolapse of the anterior mitral leaﬂet
s after the procedure. Ao  aorta; LA  left atrium; LVOT  left ventricularthetic
tral re
onthitation seem well-tolerated, and clinically significant
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817emolysis has not been observed to date (26). However,
oderately severe or severe paravalvular, albeit infre-
uent, is likely to be hemodynamically significant. The
nitial sign is typically an unexpectedly low aortic dia-
tolic pressure. Rising ventricular filling pressure might
ead to myocardial ischemia, ventricular dysfunction, and
ltimately shock. The diagnosis is confirmed with aor-
ography or, more reliably, echocardiography. Most likely
auses are incorrect positioning, undersizing, or under-
xpansion. Balloon re-expansion might be helpful in
ases of incomplete expansion, whereas a second overlap-
ing prosthesis might be the most effective solution for
eaks caused by malposition (Fig. 9). Exclusion of pa-
ients with an annulus larger than the largest available
rosthesis is prudent to avoid significant paravalvular
egurgitation. TAVI in stenotic, congenitally bicuspid
alves is possible, but experience is limited.
nnular and root rupture. Rupture of the aortic annulus is
rare complication of aortic balloon valvuloplasty (27).
imilarly, rare cases of annular or root rupture with
ubsequent hemodynamic collapse occurred with TAVI.
xcessive balloon dilation, aggressive valve oversizing,
nd extensive annular calcification might increase the
ikelihood of this uncommon complication. When the
nnulus and/or subannular tissues are markedly calcified
r when the root is unusually small, it seems prudent to
e less aggressive with balloon dilation and valve over-
izing. Unexplained hypotension after balloon dilation or
alve expansion should prompt echocardiographic or
ngiographic assessment of the LV outflow tract and
ortic root. A tear created at the level of the valve inflow
an result in either ventricular septal defect (Fig. 10) or
V to left atrial shunt (Fig. 11), whereas aortic root
upture will likely cause massive bleeding and tamponade.
Figure 9. Paravalvular Regurgitation
(A) Self-expanding valve implanted too low, resulting in severe paravalvular re
indicate the distal edge of both prostheses). (C) Mild residual paravalvular leakentricular or root rupture in the setting of TAVI carriesvery poor prognosis and is likely to require emergent
ardiopulmonary bypass and open surgical repair.
ardiac perforation. Unexplained hypotension should
rompt the consideration for cardiac tamponade. With a
etrograde approach, wire or catheter-induced LV perfo-
ation can cause tamponade. Use of a stiff wire with an
ppropriately shaped curve and a standard J-curve at the
ip is likely the best method to avoid perforation of the
V. Right heart perforation by the transvenous pace-
aker is also possible. The reported incidence of tam-
onade after TAVI varies from 0% to 7% (3–5,16).
ypically, pericardiocentesis is adequate; however, tho-
acotomy might be required.
eart block. Atrioventricular block is a known complica-
ion of surgical aortic valve replacement with reported
ncidence up to 8.2% (28). Not surprisingly, block can
lso occur with TAVI, presumably as a consequence of
he pressure applied on the conducting tissues located
ation. (B) A second prosthesis was implanted in the correct position (arrows
Figure 10. VSD
Small tear in the intra-ventricular membranous septum with left to right
shunting. LV  left ventricle; RV  right ventricle; VSD  ventricular septalgurgitdefect.
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818ubendocardially in the LV outflow tract and interven-
ricular septum. In initial reports of TAVI-induced heart
lock with the 2 currently used systems, permanent
acemaker implantation rate was 7% (29) and 18% (30),
espectively. Early experience suggests that prostheses
xtending farther in the ventricle are associated with a
igher incidence of conduction abnormalities, most likely
ew-onset left bundle branch block (30). Potential risk
actors also include aggressive oversizing and the presence
f pre-existing infranodal conduction anomalies such as
ight bundle branch block or second-degree heart block.
Heart block typically manifests immediately after valvu-
oplasty or valve implantation. Consequently, placement of
temporary pacemaker is desirable during the procedure. In
are cases heart block has appeared days after the procedure;
ost-procedural monitoring for 48 h has been suggested
30,31).
ther Complications
rrhythmia. Atrial fibrillation or ventricular ectopy might
e precipitated by cardiac manipulation and is often
oorly tolerated in the setting of aortic stenosis. Reposi-
Figure 11. Annulus Rupture
(A) Pre-implantation signiﬁcant mitral regurgitation (MR) and severe calciﬁcatio
tion, a tear (arrows) is visible at the ventricular edge of the stent, connecting
atrial shunt. (D) Autopsy proven tear of the anterior mitral curtain.ioning the ventricular wire is often all that is necessary in cases of frequent ventricular ectopy. Sustained ventricular
rrhythmias might occur spontaneously or as a conse-
uence of rapid pacing but generally are responsive to
rompt defibrillation; preparatory placement of defibril-
ator pads is advisable. Timely management of tachyar-
hythmias is important to help prevent adverse hemody-
amic consequences.
ardiogenic shock. Patients with severe aortic stenosis often
ave little myocardial reserve, particularly in the presence of
V dysfunction, hypertrophy, or coronary artery disease.
achycardia of any cause, including burst pacing, should be
inimized, and hypotension should be avoided. Whatever the
ause, hypotension or tachycardia might initiate a downward
piral of ischemia and myocardial dysfunction, leading to
hock. Vasopressor agents (phenylephrine or norepinephrine)
o maintain adequate perfusion pressure are often helpful (32),
hereas agents with a more pronounced chronotropic or
notropic effect should be avoided when possible. Rarely,
emporary femoral cardiopulmonary support might be re-
uired, although most often relief of aortic stenosis is associ-
ted with prompt improvement of the LV function and
mprovement of hemodynamic status can be expected. Should
he aortic annulus and subvalvular tissues. (B and C) After valve implanta-
ft ventricular outﬂow tract and left atrium, with large left ventricular to leftn of t
the lehest compressions be required, post-resuscitation evaluation
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819f the stent position and expansion (Fig. 6B) might be
onsidered.
cute renal failure. Aortic stenosis is often associated with
enal dysfunction due to renal pathology, medications,
nd low cardiac output. Angiographic contrast injection,
ypotension, and atheroembolism might contribute to
urther reduction of the glomerular filtration rate. How-
ver, improved renal perfusion after relief of aortic
tenosis has a salutary effect on renal function, and
lthough severe renal dysfunction and dialysis require-
ent might occur, improvement in renal function is most
ommon.
tructural valve failure. Acute valve failure has been docu-
ented very rarely. Potential causes include manufacturing
efects, leaflet damage during crimping or implantation and
nadequate closing pressure due to abnormal flow charac-
eristics. If structural valve failure is suspected to be the
ause for significant valvular regurgitation, implantation of a
econd valve within the failed valve has been shown to be a
uccessful strategy (1).
onclusions
ymptomatic aortic stenosis is associated with a dismal
rognosis. Any intervention designed to relieve aortic ste-
osis carries both the potential for benefit and risk. Im-
roved understanding of these potential risks will likely
mprove the safety and widen the potential application of
ranscatheter aortic valve replacement.
eprint requests and correspondence: Dr. John G. Webb, St.
aul’s Hospital, 1081 Burrard Street, Vancouver, BC V6Z 1Y6,
anada. E-mail: webb@providencehealth.bc.ca.
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